- Posted By: TreehillPartners
- In: Dealmaking, Financing & Capital Markets
A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past
- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.
- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development
Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.
- Posted By: TreehillPartners
- In: Leadership & Restructuring, Strategy & Corporate Development
The UK Government and EU Commission trumpeted their last minute Brexit trade deal, struck at the end of December, as comprehensive, the biggest yet. Even allowing for the hyperbole of politicians, a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements illusory for the pharma sector. In this article we summarise the extent to which the TCA really assists businesses in the sector to overcome the separation of the UK and the EU into two separate markets:
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking, Drug Development, Strategy & Corporate Development
For most emerging bio-pharma or medtech companies, establishing a development or commercialization partnership is a core component of their strategic plan, and, sealing the deal is cause for much celebration. While hard work and a number of all-nighters may go into signing an agreement, ensuring the partnership achieves its objectives and sails across the finish line is often harder, and often a bumpy ride...
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking, Drug Development, Strategy & Corporate Development
The majority of pharma and biotech venture creations are aimed at one or both of two fundamental objectives, bringing a novel therapeutic to patients and generating returns for their founders and investors. Often, pathways are poorly understood by the bootstrap team, and professional “help” is being sought from incubators, boards, investors and advisors, embedding possibly conflicting perspectives and goals into the core fabric of the company.
